Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Studies on the pharmacokinetics of piperacillin/ tazobactam in renal replacement therapy in patients with chronic renal failure

Qinqin Ma , Hongyuan Xiao, Yannan Zhang, Chen Chen, Ying Zhou, Yunning Liu, Tianmin Li, Yinghua Yu

The First Affiliated Hospital of Hebei North University, Intensive Care Unit, Hebei 075000, China;

For correspondence:- Qinqin Ma Email: shoulibenci3270@163.com

Accepted: 28 April 2021 Published: 31 May 2021

Citation: Ma Q, Xiao H, Zhang Y, Chen C, Zhou Y, Liu Y, et al. Studies on the pharmacokinetics of piperacillin/ tazobactam in renal replacement therapy in patients with chronic renal failure. Trop J Pharm Res 2021; 20(5):1073-1078 doi: 10.4314/tjpr.v20i5.27

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the pharmacokinetics of piperacillin/tazobactam in renal replacement therapy (CRRT) in patients with chronic renal failure (CRF).

Methods: Six CRF patients treated with CRRT in the First Affiliated Hospital of Hebei North University from April 2020 to July 2020 were selected and administered 4 g of piperacillin and 0.5 g of tazobactam within 30 min after, and at 5, 30, 45, 60, 90, 120, 180, 240, 360 and 480 min after CRRT. The DAS software was used to calculate pharmacokinetic parameters while linear regression was used to analyze the relationship among patient characteristics, CRRT parameters, and pharmacokinetics.

Results: The C_max of piperacillin and tazobactam was 118.46 (96.12 - 161.12) mg/L and 27.45 (14.75 - 28.45) mg/L, while the volume of distribution (V_d) was 1.16 (0.72 - 1.59) L/h and 0.72 (0.57 -0.82) L/kg, respectively. The value for elimination half-life (t_1/2) was 4.66 (3.19 -8.45) h and 4.25 (3.42 - 5.96) h, while total clearance (CL) was 7.28 (5.58 - 9.73) L/h and 6.37 (4.28 - 10.04) L/h, respectively. Multivariate linear regression showed that piperacillin C_max was negatively correlated with the flow velocity of the substitution fluid (β = -0.679, 95 % CI = -0.278 - 0.943, p < 0.001). Piperacillin CL was positively correlated with the flow velocity of the waste liquid (β = 0.956, 95 % CI = 1.267 - 4.796, p < 0.001).

Conclusion: When used in CRF patients receiving CRRT, piperacillin and tazobactam show decrease in C_max and CL, but increase in t_1/2. This finding should provide useful guidance for clinicians concerned.

Keywords: Piperacillin/tazobactam, Chronic renal failure, Renal replacement therapy, Pharmacokinetics